TRU-SENTIMENT ยท DeltaNeutral
XBI Trading Analysis - 11/20/2026 02:34 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
XBI (State Street SPDR S&P Biotech ETF) at $141.86. True Sentiment Bearish, delta 40-60 call 8% / put 92%, call $274,220 vs put $3,108,080. RSI 35.9.
- Symbol
- XBI
- Price
- $141.86
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- medium
- Published
- 2026-11-20 14:34:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Methodology: Delta 40-60 options only. Timestamp 2026-11-20 14:33.
Call Dollar Volume: $274,220.00 (8.1%) Put Dollar Volume: $3,108,080.00 (91.9%) Total: $3,382,300.00
Call contracts 373 vs put contracts 4,804. Sentiment: Bearish. Pure directional positioning shows overwhelming put conviction (91.9% put dollar vol), suggesting near-term downside expectations. This aligns with technical weakness; no divergence between sentiment and price action.
Key Statistics: XBI
Fundamental Snapshot
Valuation
| Market cap | $9.91B |
| Shares outstanding | 70.0M |
Dividend
| Dividend yield | 0.38% |
| Annual dividend | $0.54 |
| Ex-dividend date | 2026-06-22 |
Risk & range
| Beta | 1.01 |
| 52-week low | $113.57 |
| 52-week high | $169.89 |
| Historical volatility | 39.2% |
Ownership & trading
| Institutional ownership | 7.7% |
| Average daily volume | 8.7M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following items use general knowledge for context only and are separate from the data-driven analysis below:
- Biotech sector ETFs like XBI have faced pressure amid broader risk-off sentiment in small-cap healthcare ahead of year-end.
- Recent FDA clinical trial setbacks across several small-cap biotech names have weighed on sector sentiment.
- Speculation around 2027 healthcare budget cuts and drug-pricing reform has increased uncertainty for speculative biotech equities.
- XBI typically exhibits high beta to interest-rate expectations; recent firming in yields has pressured the group.
- No XBI-specific earnings catalyst exists (ETF structure), but constituent volatility remains elevated into December.
Context: Headlines reflect a bearish macro/biotech backdrop that aligns with the embedded options flow showing 91.9% put dollar volume conviction and weak technicals (RSI 35.86, price below all major SMAs).
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for XBI:
- Trailing EPS: null; Forward EPS: null; Trailing PE: null; Forward PE: null; PEG Ratio: null โ valuation multiples not available for this ETF structure.
- Revenue Growth: null; Total Revenue: null; Profit Margins: null; Return on Equity: null; Debt to Equity: null; Free Cashflow: null โ not disclosed in data.
- Market Cap: $9,906,400,000.00; Shares Outstanding: 70,000,000.00; Dividend Yield: 0.38%; Dividend Rate: $0.54; Ex-Dividend: 2026-06-22.
- Beta: 1.01 (market-like systemic risk); 52-Week High: $169.89; 52-Week Low: $113.57.
- Institutional Percent: 7.71% (low sponsorship vs typical large ETFs).
- Average Volume: 8,728,000.00; Historical Volatility: 39.24%.
- Analyst Consensus / Target Mean Price: null (no analyst opinion data).
Fundamental takeaway: As an ETF, XBI carries no reportable corporate margins or EPS. The lack of valuation multiples and low institutional holding (7.71%) coincide with the weak technical and bearish options flow, showing no fundamental divergence to offset the negative technical picture.
Current Market Position
Current price per indicators: $144.47 (as of 2026-11-19 close). Minute bars show 2026-11-20 14:05 last price $141.86, down from 2026-11-19 09:30 open $145.38. Recent daily action: 2026-11-19 close $144.47 on volume 11,993,864 vs 20-day avg 7,390,593 โ high-volume decline.
Intraday momentum (minute bars): Early 2026-11-19 traded up to $146.85 then faded; by 2026-11-20 13:45โ14:05 ranged $141.31โ$142.14, closing near $141.86, showing persistent downside drift.
Technical Analysis
Technical Indicators
Price is below SMA 5 ($146.22), SMA 20 ($152.18), and SMA 50 ($153.08) โ bearish alignment, no bullish crossovers. RSI 35.86 indicates weak momentum nearing oversold but not extreme. MACD (-2.07) below signal (-1.65), histogram -0.41 confirms bearish momentum. Bollinger Bands: price at $144.47 sits just above lower band $143.33 (expansion, not squeeze). 30-day range: price near bottom (low $143.24, high $160.29), only ~1.7% above 30d low.
True Sentiment Analysis (Delta 40-60 Options)
Methodology: Delta 40-60 options only. Timestamp 2026-11-20 14:33.
Call Dollar Volume: $274,220.00 (8.1%) Put Dollar Volume: $3,108,080.00 (91.9%) Total: $3,382,300.00
Call contracts 373 vs put contracts 4,804. Sentiment: Bearish. Pure directional positioning shows overwhelming put conviction (91.9% put dollar vol), suggesting near-term downside expectations. This aligns with technical weakness; no divergence between sentiment and price action.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.